ALX Oncology Set for Breakout with Key 2026 Trial Results
AI Prediction of ALX Oncology Holdings Inc. (ALXO)
ALX Oncology is poised for significant development advancements in 2026 with key clinical trial results expected for its lead assets, evorpacept and ALX2004. The company’s focus on oncology, particularly using biomarker-driven strategies, positions it well within the biotech sector for potential growth.
ALX Oncology, a clinical-stage biotech firm, is advancing a promising pipeline with lead assets like evorpacept and ALX2004 targeting significant unmet needs in oncology. Evorpacept's upcoming data from Phase 2 trials in breast and colorectal cancers, alongside ALX2004’s Phase 1 trials in EGFR-expressing solid tumors, are pivotal for the company’s near-term valuation. The strategic focus on biomarker-driven treatments and partnerships with leading pharmaceuticals enhances ALX Oncology’s potential to deliver substantial investor returns. These catalysts, expected in the latter half of 2026, make ALX Oncology a compelling watch for biotech investors.
ALXO Report Information
Prediction Date2026-03-09
Close @ Prediction$2.21
Mkt Cap206m
IPO DateN/a
AI-derived Information
Recent News for ALXO
- Jun 11, 4:02 pm — ALXO files 8-K with regulatory language (ScanScor Filing Bot)
- Jun 1, 8:00 am — ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York (GlobeNewswire)
- May 9, 8:30 am — ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary (Moby)
- May 8, 8:00 am — ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
- May 7, 8:00 am — ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression (GlobeNewswire)
- Apr 30, 8:00 am — ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 (GlobeNewswire)
- Apr 17, 4:05 pm — ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire)
- Apr 13, 8:30 am — ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer (GlobeNewswire)
- Mar 10, 11:38 am — GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma (Zacks)
- Mar 10, 11:09 am — EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y (Zacks)
- Mar 9, 10:23 am — Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study (Zacks)
- Mar 7, 8:25 am — ALX Oncology initiated with a Buy at UBS (TipRanks)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest